Targeting promiscuous heterodimerization overcomes innate resistance to ERBB2 dimerization inhibitors in breast cancer.

导出 OA

翻译打印收藏纠错

作者： Sean P,Kennedy ^[1] ; Jeremy Z R,Han ^[2] ; Neil,Portman ^[1] ; Max,Nobis ^[1] ; Jordan F,Hastings ^[3] ; Kendelle J,Murphy ^[1] ; Sharissa L,Latham ^[1] ; Antonia L,Cadell ^[1] ; Dushan,Miladinovic ^[1] ; Gabriella R,Marriott ^[1] ; Yolande E I,O'Donnell ^[1] ; Robert F,Shearer ^[1] ; James T,Williams ^[1] ; Amaya Garcia,Munoz ^[1] ; Thomas R,Cox ^[1] ; D Neil,Watkins ^[4] ; Darren N,Saunders ^[2] ; Paul,Timpson ^[1] ; Elgene,Lim ^[3] ; Walter,Kolch ^[1] ; David R,Croucher ^[3]

作者单位： The Kinghorn Cancer Centre, Garvan Institute of Medical Research, 370 Victoria St, Darlinghurst, Sydney, NSW, 2010, Australia. ^[1] Systems Biology Ireland, University College Dublin, Belfield, Dublin 4, Ireland. ^[2] St Vincent's Hospital Clinical School, University of New South Wales, Sydney, NSW, 2052, Australia. ^[3] School of Medicine, University of Notre Dame, Sydney, NSW, 2011, Australia. ^[4] School of Medical Sciences, University of New South Wales, Sydney, NSW, 2025, Australia. ^[5] Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Belfield, Dublin 4, Ireland. ^[6] School of Medicine and Medical Science, University College Dublin, Belfield, Dublin 4, Ireland. ^[7] The Kinghorn Cancer Centre, Garvan Institute of Medical Research, 370 Victoria St, Darlinghurst, Sydney, NSW, 2010, Australia. d.croucher@garvan.org.au. ^[8] St Vincent's Hospital Clinical School, University of New South Wales, Sydney, NSW, 2052, Australia. d.croucher@garvan.org.au. ^[9] School of Medicine and Medical Science, University College Dublin, Belfield, Dublin 4, Ireland. d.croucher@garvan.org.au. ^[10]

关键词 Breast cancer ERBB2 Heterodimers Pertuzumab Receptor tyrosine kinases